This website (hereinafter the “Website“) is provided by Bayer Middle East FZE, Dubai, U.A.E (hereinafter “us” or “we”). For further information regarding the provider of the Website, please refer to our imprint.
1. Aspirin C PIL
2. Aspirin protect PIL
3. NATIONAL ACADEMY PRESS Washington, D.C. 1987
4. Aspirin 500 PIL
5. World Health Organization, Media Centre, Fact sheet N°277, Headache Disorders, October 2012
6. Source: http://www.nhs.uk/conditions/headaches-tension-type/Pages/Introduction.aspx
10. Standards of Medical Care in Diabetes 2016 January 2016 Volume 39, Supplement 1
18. Aspirin is Efficacious for the treatment of acute migraine Lipton_et_al-2005-Headache__The_Journal_of_Head_and
19. Aspirin and tension-type headache - Ivano Farinelli , Paolo MartellettiJ - Headache Pain (2007) 8:49–55
26. Terrie YC. Stopping the Symptoms of Cough, Cold, and Flu-When recommending OTC products for these common ailments, a careful patient assessment is an important first step. Pharmacy Times 2012; 78: 12
34. A Statement for Healthcare Professionals From the American Heart Association and the Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations Circulation. 1999;100:1481-1492
37. Source: Assessment and Management of Conditions Specifically Related to Stress: mhGAP Intervention Guide Module (version 1.0). Geneva: WHO, 2013.
38. Antithrombotic Trialists’ (ATT) Collaboration* Lancet 2009; 373: 1849–60
39. ANDREW SZCZEKLIK - THE HISTORY OF ASPIRIN THE DISCOVERIE Paths of Discovery Pontifical Academy of Sciences, Acta 18, Vatican City 2006 http://www.pas.va/content/dam/accademia
41. Heart Disease, Stroke and Research Statistics At-a-Glance https://www.heart.org/idc/groups/ahamah-public/@wcm/@sop/@smd/documents/
43. Review Article The mechanism of action of aspirin J.R. Vane, R.M. Botting ; Thrombosis Research 110 (2003) 255–258
44. Aspirin the novel antiplatelet drug D Pawar, S Shahani, S Maroli HKMJ 1998;4:415-8
46. Evaluation of the Benefit and risk of low dose Aspirin is the secondary prevention of cardio vascular and cerebrovascular events Steven M Weisman , David Y. Graham ; Arch intern Med 2002 162:2 197-2202
47. Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989;321(3):129–135
48. The Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978;299:53–59
49. WHO - Global atlas on cardiovascular disease prevention and control 2011
53. Walter Sneader, The discovery of aspirin: a reappraisal, BMJ. 2000 Dec 23; 321(7276): 1591–1594.
54. Kagan Ipci et al, Effervescent tablets: a safe and practical delivery system for drug administration, ENT Updates 2016;6(1):46–50
57. David Gregg, et al, Platelets and Cardiovascular Disease, Circulation. 2003;108:e88-e90
59. COCEANI et al, Prostaglandin E2 And Fever: A Continuing Debate THE YALE JOURNAL OF BIOLOGY AND MEDICINE 59 (1986), 169-174
60. Vane, J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirinlike drugs.Nature (London) New Biology 231:232-235, 1971.
63. F. E. Young et al, “The Preliminary Report of the Findings of the Aspirin Component of the Ongoing Physicians” Health Study, JAMA 1988
65. WHO updates Cardiovascular Risk Charts. Available at https://www.who.int/news-room/detail/02-09-2019-who-updates-cardiovascular-risk-charts last accessed April 5, 2020.
66. Rugge B, Balshem H, Sehgal R, et al. Screening and Treatment of Subclinical Hypothyroidism or Hyperthyroidism [Internet] Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Oct. (Comparative Effectiveness Reviews, No. 24.) Appendix A, Lipid Conversion Factors. Available from: https://www.ncbi.nlm.nih.gov/books
/NBK83505/ last accessed April 5, 2020.
67. Framingham Heart Study, Cardiovascular disease (10 year) risk. Available at https://framinghamheartstudy.org/fhs-risk-functions/cardiovascular-disease-10-year-risk/?CDC_AA_refVal=https%3A%2F%2F
%2Fheartage.html last accessed April 5, 2020.
68. American Heart Association and American Stroke Association, FACTS What Are You Smoking? Smoking and Cardiovascular Disease (CVD). Available at http://www.heart.org/idc/groups/heart-public/@wcm/@adv/documents/
downloadable/ucm_304555.pdf last accessed April 2, 2020.
69. Reena S Shah & John W Cole, Smoking and stroke: the more you smoke the more you stroke, Journal Expert Review of Cardiovascular Therapy Volume 8, 2010 - Issue 7.
70. Center for Disease Control and Prevention, Diabetes and Your Heart. Available at https://www.cdc.gov/diabetes/library/
features/diabetes-and-heart.html last accessed April 2, 2020.
71. Center for Disease Control and Prevention, Know Your Risk for Heart Disease. Available at https://www.cdc.gov/heartdisease/
risk_factors.htm last accessed April 2, 2020.
72. Paul Poirier et al, Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss, Circulation, February 2006. DOI http://dx.doi.org/10.1161/circulationaha.106
73. American Heart Association, Lifestyle Changes for Heart Attack Prevention. Available at https://www.heart.org/en/health-topics/heart-attack/life-after-a-heart-attack/lifestyle-changes-for-heart-attack-prevention last accessed April 2, 2020.
74. National Heart Foundation of Australia, Heart Age Calculator. Available at https://www.heartfoundation.org.au/your-heart/know-your-risks/heart-age-calculator last accessed April 2, 2020.